{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T13:44:38Z","timestamp":1780321478018,"version":"3.54.1"},"reference-count":32,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100011251","name":"NOAMA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011251","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","heartrhythmjournal.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart Rhythm"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.hrthm.2024.06.010","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T17:52:37Z","timestamp":1718301157000},"page":"2397-2406","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparative effectiveness and safety of apixaban and rivaroxaban in older patients with atrial fibrillation: A population-based cohort study"],"prefix":"10.1016","volume":"21","author":[{"given":"Mohammed","family":"Shurrab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter C.","family":"Austin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia A.","family":"Jackevicius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Haldenby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Middleton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mintu P.","family":"Turakhia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato D.","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E.","family":"Boden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lana A.","family":"Castellucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"Heidenreich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeff S.","family":"Healey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis T.","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hrthm.2024.06.010_bib1","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0735-1097(00)01107-4","article-title":"Epidemiology and natural history of atrial fibrillation: clinical implications","volume":"37","author":"Chugh","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2024.06.010_bib2","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.113.005119","article-title":"Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study","volume":"129","author":"Chugh","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2024.06.010_bib3","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1161\/CIRCRESAHA.120.316340","article-title":"Epidemiology of atrial fibrillation in the 21st century: novel methods and new insights","volume":"127","author":"Kornej","year":"2020","journal-title":"Circ Res"},{"key":"10.1016\/j.hrthm.2024.06.010_bib4","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/NRL.0b013e31815cffae","article-title":"Clinical epidemiology of atrial fibrillation and related cerebrovascular events in the United States","volume":"14","author":"Lakshminarayan","year":"2008","journal-title":"Neurologist"},{"key":"10.1016\/j.hrthm.2024.06.010_bib5","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.amjcard.2017.08.014","article-title":"Temporal trends in the incidence, prevalence, and survival of patients with atrial fibrillation from 2004 to 2016","volume":"120","author":"Williams","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hrthm.2024.06.010_bib6","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/phar.2158","article-title":"Trends and variation in oral anticoagulant choice in patients with atrial fibrillation, 2010-2017","volume":"38","author":"Zhu","year":"2018","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.hrthm.2024.06.010_bib7","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.amjcard.2022.10.031","article-title":"Association between concurrent use of amiodarone and DOACs and risk of bleeding in patients with atrial fibrillation","volume":"186","author":"Shurrab","year":"2023","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.hrthm.2024.06.010_bib8","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/j.cjca.2013.04.002","article-title":"Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban","volume":"29","author":"Gong","year":"2013","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.hrthm.2024.06.010_bib9","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.hrthm.2024.06.010_bib10","article-title":"Rivaroxaban versus apixaban for stroke prevention in atrial fibrillation: an instrumental variable analysis of a nationwide cohort","volume":"13","author":"Bonde","year":"2020","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.hrthm.2024.06.010_bib11","doi-asserted-by":"crossref","first-page":"463","DOI":"10.7326\/M19-2522","article-title":"Effectiveness and safety of apixaban compared with rivaroxaban for patients with atrial fibrillation in routine practice: a cohort study","volume":"172","author":"Fralick","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.hrthm.2024.06.010_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-064662","article-title":"Using primary care data to assess comparative effectiveness and safety of apixaban and rivaroxaban in patients with nonvalvular atrial fibrillation in the UK: an observational cohort study","volume":"12","author":"Jaksa","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.hrthm.2024.06.010_bib13","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.chest.2016.07.013","article-title":"Direct comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation","volume":"150","author":"Noseworthy","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.hrthm.2024.06.010_bib14","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1001\/jama.2021.21222","article-title":"Association of rivaroxaban vs apixaban with major ischemic or hemorrhagic events in patients with atrial fibrillation","volume":"326","author":"Ray","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.hrthm.2024.06.010_bib15","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1001\/jamainternmed.2020.1835","article-title":"Risk of hospitalization with hemorrhage among older adults taking clarithromycin vs azithromycin and direct oral anticoagulants","volume":"180","author":"Hill","year":"2020","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.hrthm.2024.06.010_bib16","first-page":"279","article-title":"Safety of switching from a vitamin K antagonist to a non-vitamin K antagonist oral anticoagulant in frail older patients with atrial fibrillation: results of the FRAIL-AF randomized controlled trial","volume":"149","author":"Joosten","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.hrthm.2024.06.010_bib17","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.cjca.2016.06.006","article-title":"Identifying patients with atrial fibrillation in administrative data","volume":"32","author":"Tu","year":"2016","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.hrthm.2024.06.010_bib18","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1016\/S0140-6736(18)30668-8","article-title":"Development and validation of a Hospital Frailty Risk Score focusing on older people in acute care settings using electronic hospital records: an observational study","volume":"391","author":"Gilbert","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.hrthm.2024.06.010_bib19","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1002\/sim.2580","article-title":"A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study","volume":"26","author":"Austin","year":"2007","journal-title":"Stat Med"},{"key":"10.1016\/j.hrthm.2024.06.010_bib20","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1002\/sim.6607","article-title":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","volume":"34","author":"Austin","year":"2015","journal-title":"Stat Med"},{"key":"10.1016\/j.hrthm.2024.06.010_bib21","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1002\/sim.5705","article-title":"The performance of different propensity score methods for estimating marginal hazard ratios","volume":"32","author":"Austin","year":"2013","journal-title":"Stat Med"},{"key":"10.1016\/j.hrthm.2024.06.010_bib22","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","article-title":"Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study","volume":"285","author":"Go","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.hrthm.2024.06.010_bib23","doi-asserted-by":"crossref","first-page":"774","DOI":"10.7326\/M18-1523","article-title":"Interventions for preventing thromboembolic events in patients with atrial fibrillation: a systematic review","volume":"169","author":"Lowenstern","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.hrthm.2024.06.010_bib24","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1016\/j.clinthera.2015.09.008","article-title":"Trends in prescribing oral anticoagulants in Canada, 2008-2014","volume":"37","author":"Weitz","year":"2015","journal-title":"Clin Ther"},{"key":"10.1016\/j.hrthm.2024.06.010_bib25","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.7326\/M22-0511","article-title":"Comparative effectiveness and safety between apixaban, dabigatran, edoxaban, and rivaroxaban among patients with atrial fibrillation: a multinational population-based cohort study","volume":"175","author":"Lau","year":"2022","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.hrthm.2024.06.010_bib26","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/j.cjca.2020.09.001","article-title":"The 2020 Canadian Cardiovascular Society\/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation","volume":"36","author":"Andrade","year":"2020","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.hrthm.2024.06.010_bib27","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.jacc.2019.01.011","volume":"74","author":"January","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.hrthm.2024.06.010_bib28","article-title":"Oral anticoagulants for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis, and cost effectiveness analysis","volume":"359","author":"L\u00f3pez-L\u00f3pez","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.hrthm.2024.06.010_bib29","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ijcard.2018.06.114","article-title":"A systematic review of network meta-analyses among patients with nonvalvular atrial fibrillation: a comparison of efficacy and safety following treatment with direct oral anticoagulants","volume":"269","author":"Cohen","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.hrthm.2024.06.010_bib31","article-title":"Preferences for and use of oral anticoagulants for stroke prevention in atrial fibrillation under real-world conditions in Germany: a survey among physicians","volume":"28","author":"Mocek","year":"2022","journal-title":"Prev Med Rep"},{"key":"10.1016\/j.hrthm.2024.06.010_bib32","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.cjco.2021.09.002","article-title":"Association of sex with stroke and bleeding risk of apixaban and rivaroxaban in elderly atrial fibrillation patients using propensity score weights","volume":"4","author":"Gulilat","year":"2022","journal-title":"CJC Open"},{"key":"10.1016\/j.hrthm.2024.06.010_bib33","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/phar.2350","article-title":"Oral anticoagulant prescription trends, profile use, and determinants of adherence in patients with atrial fibrillation","volume":"40","author":"Perreault","year":"2020","journal-title":"Pharmacotherapy"}],"container-title":["Heart Rhythm"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1547527124026869?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1547527124026869?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T13:33:19Z","timestamp":1732714399000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1547527124026869"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1547527124026869"],"URL":"https:\/\/doi.org\/10.1016\/j.hrthm.2024.06.010","relation":{},"ISSN":["1547-5271"],"issn-type":[{"value":"1547-5271","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative effectiveness and safety of apixaban and rivaroxaban in older patients with atrial fibrillation: A population-based cohort study","name":"articletitle","label":"Article Title"},{"value":"Heart Rhythm","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hrthm.2024.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Heart Rhythm Society. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}